Research and Development Investment: Corcept Therapeutics Incorporated vs Amicus Therapeutics, Inc.

Biotech R&D: Amicus vs. Corcept's Decade of Investment

__timestampAmicus Therapeutics, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 20144762400018372000
Thursday, January 1, 20157694300015419000
Friday, January 1, 201610479300023844000
Sunday, January 1, 201714931000040376000
Monday, January 1, 201827090200075247000
Tuesday, January 1, 201928637800089017000
Wednesday, January 1, 2020308443000114764000
Friday, January 1, 2021272049000113864000
Saturday, January 1, 2022276677000130991000
Sunday, January 1, 2023152381000184353000
Loading chart...

Igniting the spark of knowledge

A Decade of R&D Investment: Corcept vs. Amicus

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amicus consistently outpaced Corcept, with its R&D expenses peaking at nearly 308 million in 2020, a staggering 550% increase from 2014. In contrast, Corcept's R&D spending grew more modestly, reaching its highest point in 2023 with an investment of approximately 184 million, marking a tenfold increase since 2014. This divergence highlights Amicus's aggressive pursuit of new therapies, while Corcept's steady growth reflects a more measured approach. As the biotech sector continues to evolve, these investment patterns may offer insights into each company's future trajectory and potential breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025